Literature DB >> 29673911

Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension.

Cheng Li1, Ping-Ping Liu2, Dou-Dou Tang1, Rong Song1, Yi-Qing Zhang1, Si Lei1, Shang-Jie Wu3.   

Abstract

BACKGROUND: Hypoxic pulmonary arterial hypertension (PAH) is a crippling disease with limited therapeutic methods. The imbalance of T helper 17 cell (Th17)/regulatory T cell (Treg) plays an important role in the development of Hypoxic PAH. However, whether targeting the ras homolog family member A-Rho kinase (RhoA-ROCK) pathway (activation and inhibition) by lysophosphatidic acid (LPA) and fasudil (FSD) regulate T-cell homeostasis in Hypoxic PAH remain unknown.
OBJECTIVE: To examine the effects of LPA and FSD on hypoxic pulmonary vascular remodeling and homeostasis of Th17/Treg cells in Hypoxic PAH.
METHODS: Rats were exposed to hypoxia (10 ± 0.5% O2) to induce Hypoxic PAH. The experiments consists of two parts. Forty rats were randomly divided into four groups (n = 10): normoxia group, normoxia + LPA group, hypoxia group and hypoxia + LPA group. Thirty rats were randomly divided into another three groups (n = 10): normoxia group, hypoxia group, and hypoxia + FSD group. Rats in normoxia + LPA group and hypoxia + LPA group were intraperitoneally injected 40 μg/kg LPA daily. Rats in hypoxia + FSD group were intraperitoneally injected 30 mg/kg fasudil daily. The effects of LPA and FSD on the development of hypoxic PAH and right ventricle (RV) hypertrophy, on pulmonary vascular remodeling, and on changes of Th17/Treg cells and levels of interleukin-17 (IL-17) and IL-10 were examined.
RESULTS: PAH and RV hypertrophy occurred in rats exposed to hypoxia. LPA exacerbated hypoxic pulmonary vascular remodeling and FSD inhibited it. LPA increased Th17/Treg imbalance in peripheral blood and spleen. However, after treatment with FSD, hypoxic PAH rats showed an obvious reduction of Th17 cells as well as an increase of Treg cells. LPA increased the expression of phosphorylated-signal transducer and activator of transcription 3 (p-STAT3) and reduced the p-STAT5 in peripheral blood and spleen in hypoxic PAH rats. The expression of p-STAT3 and p-STAT5 in hypoxic PAH rats treated with FSD showed opposite changes. LPA increased the expression of IL-17 and reduced the IL-10 in small intrapulmonary arteries and serum in hypoxic PAH. However, the expression of IL-17 and IL-10 in hypoxic PAH rats treated with FSD showed opposite changes.
CONCLUSIONS: Activation and inhibition of RhoA-ROCK pathway by LPA and FSD modulated the homeostasis of Th17/Treg cells via regulating STAT3/STAT5 phosphorylation in hypoxic PAH. Thus, Apart from influence of pulmonary vascular remodeling, regulation of Th17/Treg homeostasis by RhoA-ROCK pathway play a key role in hypoxic PAH.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fasudil; Hypoxic pulmonary arterial hypertension; Lysophosphatidic acid; Regulatory T cell; T helper 17 cell

Mesh:

Substances:

Year:  2018        PMID: 29673911     DOI: 10.1016/j.pupt.2018.04.004

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  9 in total

Review 1.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  LPA suppresses T cell function by altering the cytoskeleton and disrupting immune synapse formation.

Authors:  Kimberly N Kremer; Alan Buser; Dean Thumkeo; Shuh Narumiya; Jordan Jacobelli; Roberta Pelanda; Raul M Torres
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-08       Impact factor: 12.779

3.  Abnormal pulmonary artery systolic pressure response after exercise in systemic sclerosis patients: A PRISMA-compliant meta-analysis.

Authors:  Song Yang; Jing Wu; Si Lei; Rong Song; Ye-Yu Cai; Shang-Jie Wu
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

4.  The Role of Regulatory T Cells in Pulmonary Arterial Hypertension.

Authors:  Haihua Qiu; Yi He; Fan Ouyang; Ping Jiang; Shuhong Guo; Yuan Guo
Journal:  J Am Heart Assoc       Date:  2019-11-27       Impact factor: 5.501

Review 5.  Cardioprotection in right heart failure.

Authors:  Kerstin Boengler; Klaus-Dieter Schlüter; Ralph Theo Schermuly; Rainer Schulz
Journal:  Br J Pharmacol       Date:  2020-03-09       Impact factor: 8.739

Review 6.  Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension.

Authors:  Zhijie Yu; Jun Xiao; Xiao Chen; Yi Ruan; Yang Chen; Xiaoyuan Zheng; Qiang Wang
Journal:  Chin Med       Date:  2022-01-15       Impact factor: 5.455

Review 7.  Dysregulated Immunity in Pulmonary Hypertension: From Companion to Composer.

Authors:  Teresa C Funk-Hilsdorf; Felix Behrens; Jana Grune; Szandor Simmons
Journal:  Front Physiol       Date:  2022-02-17       Impact factor: 4.566

8.  Emergency myelopoiesis contributes to immune cell exhaustion and pulmonary vascular remodelling.

Authors:  Chunhua Fu; Yuanqing Lu; Mason A Williams; Mark L Brantly; Corey E Ventetuolo; Laurence M Morel; Borna Mehrad; Edward W Scott; Andrew J Bryant
Journal:  Br J Pharmacol       Date:  2020-02-04       Impact factor: 9.473

Review 9.  ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension.

Authors:  Tadeu L Montagnoli; Jaqueline S da Silva; Susumu Z Sudo; Aimeé D Santos; Gabriel F Gomide; Mauro P L de Sá; Gisele Zapata-Sudo
Journal:  Cells       Date:  2021-06-30       Impact factor: 7.666

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.